ARWR

Arrowhead Pharma

• TipRanks·1d ago

  H.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

• Simply Wall St·2d ago

  Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After Durable Two-Year Plozasiran Data in Severe Hypertriglyceridemia

• Simply Wall St·4d ago

  A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran Phase 2 Extension Data

• Benzinga·03/30 07:28

  Reported Saturday, Arrowhead's Plozasiran Delivers 83% Median Triglyceride Reduction In Severe hypertriglyceridemia Patients With Zero Acute Pancreatitis Events Over Two-Year Open-Label Extension Study

• TipRanks·03/29 16:00

  Arrowhead presents long-term efficacy, safety data for plozasiran

• Simply Wall St·03/28 19:10

  How Investors May Respond To Arrowhead Pharmaceuticals (ARWR) Plozasiran’s Two-Year Triglyceride and Safety Data

• Reuters·03/28 14:30

  Arrowhead says plozasiran cuts triglycerides up to 83% in two-year extension study

• TipRanks·03/27 09:45

  Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty

• Benzinga·03/26 17:47

  Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

• TipRanks·03/26 15:40

  Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (MAZE), Azitra Inc (AZTR) and Arrowhead Pharmaceuticals (ARWR)

• TipRanks·03/26 15:30

  Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink

• TipRanks·03/26 15:20

  Arrowhead price target lowered to $81 from $84 at BofA

• Seeking Alpha·03/26 11:13

  Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead

• Simply Wall St·03/26 08:10

  Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong One Year Shareholder Return

• Benzinga·03/25 18:32

  AAR Foods Posts Upbeat Q3 Earnings, Joins Braze, Arm Holdings And Other Big Stocks Moving Higher On Wednesday